TissueGen, developer of cutting-edge absorbable polymer technology for implantable drug delivery, is set to present its Elute fibre, a groundbreaking biodegradable fibre format for advanced drug delivery, nerve regeneration, and tissue engineering, at MD&M East expo, to be held from June 9 to 11, 2015, at New York.

The company’s patented, cutting edge room temperature extrusion process enables loading of Elute fibres with the widest range possible of drugs and biologically-derived entities including temperature sensitive proteins, growth factors, enzymes, small molecule pharmaceuticals, and viruses. Elute fibres are available in pharmaceutical and growth factor formats ideal for a wide variety of medical and research applications including spinal cord injury repair, tissue engineering and nerve regeneration, according to a company press release.

Elute fibres can directly replace standard fibres used in biodegradable textiles and provide significantly improved clinical outcomes by adding therapeutic agents directly at the site of the implant. By delivering drugs at the site of implantation, Elute fibres enable medical devices to tailor the body’s response. Frequently, localized drug delivery is preferred over systemic delivery. Additionally, TissueGen’s drug loaded biodegradable fibres stay in place once implanted, whereas drugs injected via millions of microspheres or billions of nanoparticles cannot be retrieved from the body, implantables with Elute fibres may be retrieved as required by the treating physician.

TissueGen works with leading medical device and medical textile partners to deliver fibre and textile platforms for use in drug-eluting medical device applications such as small diameter vascular grafts and stents, tissue and nerve regeneration, orthopaedics, and sutures. (GK)